DOW JONES21,052.53-360.91 -1.69%
S&P 5002,488.65-38.25 -1.51%
NASDAQ7,373.08-114.23 -1.53%

UPDATE: Cantor Fitzgerald On Novavax Also Sees Potential Value 'based on Co.'s platform recombinant nanoparticle and Matrix-M adjuvant technologies, including its influenza/RSV programs, its emerging infectious disease programs and licensing of Matrix-M for use in other vaccines.'

- Dow Jones  

Dow Jones   · 03/18/2020 13:59